Mantle cell lymphoma medical therapy

Revision as of 06:04, 4 January 2019 by Farima Kahe (talk | contribs)
Jump to navigation Jump to search

Mantle cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Mantle cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Mantle cell lymphoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Mantle cell lymphoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Mantle cell lymphoma medical therapy

on Mantle cell lymphoma medical therapy

Mantle cell lymphoma medical therapy in the news

Blogs on Mantle cell lymphoma medical therapy

Directions to Hospitals Treating Mantle cell lymphoma

Risk calculators and risk factors for Mantle cell lymphoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]

Overview

The mainstay of treatment for mantle cell lymphoma is chemotherapy. However, immunotherapy, radioimmunotherapy, targeted therapy using newer biologic agents and stem cell transplantation are also used along with chemotherapy to treat the disease. Mantle cell lymphoma shows a heterogeneous clinical behavior, with some patients having indolent disease whereas a vast majority show aggressive presentation. Most of the patients eventually relapse and have disease progression after treatment. Hence, mantle cell lymphoma is still considered an incurable disease and there is no consensus among oncologists about its optimal treatment. It is therefore recommended that mantle cell lymphoma patients are seen by physicians having extensive experience in dealing with mantle cell lymphoma and they are also encouraged to participate in clinical trials to get the latest treatments.

Medical Therapy

Mantle cell lymphoma shows a heterogeneous clinical behavior, with some patients having indolent disease whereas a vast majority show aggressive presentation. Most of the patients eventually relapse and have disease progression after treatment. Hence, mantle cell lymphoma is still considered an incurable disease and there is no consensus among oncologists about its optimal treatment. It is therefore recommended that mantle cell lymphoma patients are seen by physicians having extensive experience in dealing with mantle cell lymphoma and they are also encouraged to participate in clinical trials to get the latest treatments.

Stage I-II:

  • Radiotherapy alone or combination chemoimmunotherapy with or without radiotherapy is recommended.[1]
  • For patients with complete response(CR), clinical followup is conducted every 3-6 months for 5 years, and then on a yearly basis.
  • For patients treated with radiotherapy alone initially, disease progression and relapses after a CR or partial response(PR) is treated with first-line induction therapy (recommended for stage II bulky and stage II-IV disease)
  • For patients treated with chemoimmunotherapy with or without radiotherapy, disease progression and relapses after a CR or PR is treated with second-line therapy regimens (recommended for stage II bulky and stage II-IV disease)

Stage II (bulky) and Stage III-IV:

First-line induction therapy:

First-line consolidation therapy:

  • HDT/ASCR is recommended.[3]
  • Patients who are not HDT/ASCR candidates, and are in remission after R-CHOP therapy, may get rituximab maintenance therapy every 8 weeks.

Second-line therapy:

References